Search Results - "Le, Xiuning"

Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer by Vokes, Natalie I., Pan, Kelsey, Le, Xiuning

“…For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven…”
Get full text

β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers by Nilsson, Monique B., Le, Xiuning, Heymach, John V.

“…Lung cancer results in more patient deaths each year than any other cancer type. Additional treatment strategies are needed to improve clinical responses to…”
Get full text

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer by Hong, Lingzhi, Zhang, Jianjun, Heymach, John V., Le, Xiuning

“…It has been over three decades since the hepatocyte growth factor (HGF) ligand and its receptor MET proto-oncogene (MET) pathway was established as promoting…”
Get full text

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC by Le, Xiuning, Puri, Sonam, Negrao, Marcelo V, Nilsson, Monique B, Robichaux, Jacqulyne, Boyle, Theresa, Hicks, J Kevin, Lovinger, Katherine L, Roarty, Emily, Rinsurongkawong, Waree, Tang, Ming, Sun, Huiying, Elamin, Yasir, Lacerda, Lara C, Lewis, Jeff, Roth, Jack A, Swisher, Stephen G, Lee, J Jack, William, Jr, William N, Glisson, Bonnie S, Zhang, Jianjun, Papadimitrakopoulou, Vassiliki A, Gray, Jhanelle E, Heymach, John V

“…Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of -mutant NSCLC…”
Get full text

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma by Rangachari, Deepa, VanderLaan, Paul A, Shea, Meghan, Le, Xiuning, Huberman, Mark S, Kobayashi, Susumu S, Costa, Daniel B

“…Targeted somatic genomic analysis (EGFR, anaplastic lymphoma receptor tyrosine kinase gene [ALK], and ROS1) and programmed death ligand 1 (PD-L1) tumor…”
Get more information

Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer by Chen, Ming, Chen, Runzhe, Jin, Ying, Li, Jun, Hu, Xin, Zhang, Jiexin, Fujimoto, Junya, Hubert, Shawna M., Gay, Carl M., Zhu, Bo, Tian, Yanhua, McGranahan, Nicholas, Lee, Won-Chul, George, Julie, Hu, Xiao, Chen, Yamei, Wu, Meijuan, Behrens, Carmen, Chow, Chi-Wan, Pham, Hoa H. N., Fukuoka, Junya, Wu, Jia, Parra, Edwin Roger, Little, Latasha D., Gumbs, Curtis, Song, Xingzhi, Wu, Chang-Jiun, Diao, Lixia, Wang, Qi, Cardnell, Robert, Zhang, Jianhua, Wang, Jing, Le, Xiuning, Gibbons, Don L., Heymach, John V., Jack Lee, J., William, William N., Cheng, Chao, Glisson, Bonnie, Wistuba, Ignacio, Andrew Futreal, P., Thomas, Roman K., Reuben, Alexandre, Byers, Lauren A., Zhang, Jianjun

“…Small-cell lung cancer (SCLC) is speculated to harbor complex genomic intratumor heterogeneity (ITH) associated with high recurrence rate and suboptimal…”
Get full text

Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review by Al-Tashi, Qasem, Saad, Maliazurina B, Muneer, Amgad, Qureshi, Rizwan, Mirjalili, Seyedali, Sheshadri, Ajay, Le, Xiuning, Vokes, Natalie I, Zhang, Jianjun, Wu, Jia

“…The identification of biomarkers plays a crucial role in personalized medicine, both in the clinical and research settings. However, the contrast between…”
Get full text

AI in drug discovery and its clinical relevance by Qureshi, Rizwan, Irfan, Muhammad, Gondal, Taimoor Muzaffar, Khan, Sheheryar, Wu, Jia, Hadi, Muhammad Usman, Heymach, John, Le, Xiuning, Yan, Hong, Alam, Tanvir

“…The COVID-19 pandemic has emphasized the need for novel drug discovery process. However, the journey from conceptualizing a drug to its eventual implementation…”
Get full text

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance by Nilsson, Monique B., Yang, Yan, Heeke, Simon, Patel, Sonia A., Poteete, Alissa, Udagawa, Hibiki, Elamin, Yasir Y., Moran, Cesar A., Kashima, Yukie, Arumugam, Thiruvengadam, Yu, Xiaoxing, Ren, Xiaoyang, Diao, Lixia, Shen, Li, Wang, Qi, Zhang, Minying, Robichaux, Jacqulyne P., Shi, Chunhua, Pfeil, Allyson N., Tran, Hai, Gibbons, Don L., Bock, Jason, Wang, Jing, Minna, John D., Kobayashi, Susumu S., Le, Xiuning, Heymach, John V.

“…Effective therapeutic strategies are needed for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations that acquire…”
Get full text

Locally Advanced, Unresectable Non-Small Cell Lung Cancer by Puri, Sonam, Saltos, Andreas, Perez, Bradford, Le, Xiuning, Gray, Jhanelle E.

“…Purpose of Review Treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) has recently been revolutionized by the incorporation of…”
Get full text

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer by Le, Xiuning, Antony, Rajee, Razavi, Pedram, Treacy, Daniel J, Luo, Flora, Ghandi, Mahmoud, Castel, Pau, Scaltriti, Maurizio, Baselga, Jose, Garraway, Levi A

“…PIK3CA (which encodes the PI3K alpha isoform) is the most frequently mutated oncogene in breast cancer. Small-molecule PI3K inhibitors have shown promise in…”
Get more information

CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma by Rocha, Pedro, Salazar, Ruth, Zhang, Jiexin, Ledesma, Debora, Solorzano, Jose L., Mino, Barbara, Villalobos, Pamela, Dejima, Hitoshi, Douse, Dzifa Y., Diao, Lixia, Mitchell, Kyle Gregory, Le, Xiuning, Zhang, Jianjun, Weissferdt, Annikka, Parra-Cuentas, Edwin, Cascone, Tina, Rice, David C., Sepesi, Boris, Kalhor, Neda, Moran, Cesar, Vaporciyan, Ara, Heymach, John, Gibbons, Don L., Lee, J. Jack, Kadara, Humam, Wistuba, Ignacio, Behrens, Carmen, Solis, Luisa Maren

“…Introduction CD73 is a membrane-bound enzyme crucial in adenosine generation. The adenosinergic pathway plays a critical role in immunosuppression and in…”
Get full text

Antibody-drug conjugates in lung cancer: dawn of a new era? by Coleman, Niamh, Yap, Timothy A., Heymach, John V., Meric-Bernstam, Funda, Le, Xiuning

“…Antibody-drug conjugates (ADCs) are one of fastest growing classes of oncology drugs in modern drug development. By harnessing the powers of both cytotoxic…”
Get full text

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation by Jin, Ying, Bao, Hua, Le, Xiuning, Fan, Xiaojun, Tang, Ming, Shi, Xun, Zhao, Jun, Yan, Junrong, Xu, Yang, Quek, Kelly, Elamin, Yasir Y., Zhang, Jianhua, Futreal, P. Andrew, Wistuba, Ignacio I., Heymach, John V., Lou, Guangyuan, Shao, Lan, He, Qiong, Lin, Chen, Wu, Xue, Shao, Yang W., Wang, Xiaonan, He, Jiachen, Chen, Yamei, Stebbing, Justin, Chen, Ming, Zhang, Jianjun, Yu, Xinmin

“…EGFR -mutant non-small-cell lung cancer (NSCLC) patients inevitably develop drug resistance when treated with EGFR tyrosine kinase inhibitors (TKIs)…”
Get full text

Targeting the MET gene: unveiling therapeutic opportunities in immunotherapy within the tumor immune microenvironment of non-small cell lung cancer by Ye, Lisha, Wang, Wenjing, Li, Huihui, Ji, Yongling, Le, Xiuning, Xu, Xiaoling

“…Non-small cell lung cancer (NSCLC) represents the most prevalent histological subtype of lung cancer. Within this disease, the MET gene emerges as a critical…”
Get full text

Effects of RAS on the genesis of embryonal rhabdomyosarcoma by Langenau, David M, Keefe, Matthew D, Storer, Narie Y, Guyon, Jeffrey R, Kutok, Jeffery L, Le, Xiuning, Goessling, Wolfram, Neuberg, Donna S, Kunkel, Louis M, Zon, Leonard I

“…Embryonal rhabdomyosarcoma (ERMS) is a devastating cancer with specific features of muscle differentiation that can result from mutational activation of RAS…”
Get full text

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients by Le, Xiuning, Goldman, Jonathan Wade, Clarke, Jeffrey Melson, Tchekmedyian, Nishan, Piotrowska, Zofia, Chu, David, Bhat, Gajanan, Lebel, Francois M., Socinski, Mark A.

“…Abstract only 9514 Background: Treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 mutations is an unmet medical need. Poziotinib is a potent…”
Get full text

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group by Jiang, Tao, Su, Chunxia, Ren, Shengxiang, Cappuzzo, Federico, Rocco, Gaetano, Palmer, Joshua D, van Zandwijk, Nico, Blackhall, Fiona, Le, Xiuning, Pennell, Nathan A, Zhou, Caicun

“…The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have brought substantial clinical benefit to patients…”
Get full text

Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening by Nofal, Sara, Niu, Jiangong, Resong, Paul, Jin, Jeff, Merriman, Kelly W., Le, Xiuning, Katki, Hormuzd, Heymach, John, Antonoff, Mara B., Ostrin, Edwin, Wu, Jia, Zhang, Jianjun, Toumazis, Iakovos

“…Background Personal history of cancer is an independent risk factor for lung cancer but is omitted from existing lung cancer screening eligibility criteria. In…”
Get full text

Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features by Li, Hui, Hu, Xin, Ning, Matthew S, Fuller, Gregory N, Stewart, John M, Gilliam, Jared C, Wu, Jia, Le, Xiuning, Vaporciyan, Ara A, Lee, J Jack, Gibbons, Don L, Heymach, John V, Futreal, Andrew, Zhang, Jianjun

“…Accurate diagnoses are crucial in determining the most effective treatment across different cancers. In challenging cases, morphology-based traditional…”
Get full text